CBD Guides

CBD and drug interactions: which medicines need real care?

By the Honest CBD Co team · 30th August 2026 · Updated 1st September 2026

CBD can change how the liver breaks down many prescription medicines, and some combinations carry real risk. The greatest danger sits with narrow therapeutic index drugs, including warfarin, tacrolimus, and certain antiepileptics, where small shifts in blood levels can cause bleeding, toxicity, or treatment failure. If you take any regular medication, tell your doctor or pharmacist before starting or stopping CBD, and never assume “natural” means “risk-free.”

TL;DR:

CBD can significantly increase blood levels of narrow therapeutic index drugs like warfarin and tacrolimus, risking toxicity or bleeding.

The interaction with CBD depends on dose, the specific medication, and which liver enzyme pathways they rely on, often requiring close monitoring.

Patients on these high-risk medications should disclose CBD use to all healthcare providers and have their drug levels monitored immediately after starting or changing CBD.

Variability in CBD product quality, including label accuracy and contamination, can alter interaction risks and complicate clinical assessments.

Using interaction-checking tools, and knowing the exact strength and contents of your CBD product, helps your clinician manage the risk properly.

How CBD changes the way drugs are metabolised
Which medicines carry the highest risk with CBD
What the evidence on CBD medicine interactions actually shows
Exactly what to do if you take medicines and want to use CBD
Why product quality changes the interaction risk too
Tools that help you check CBD and drug interactions
A note on how we think about CBD and medication safety
Why the “just tell your doctor” advice usually falls short
Sources

How CBD changes the way drugs are metabolised

CBD doesn’t just sit quietly alongside your other medicines. It actively interferes with the enzymes your liver uses to break drugs down, and that interference is the entire reason interaction warnings exist.

Most oral drugs pass through the cytochrome P450 (CYP450) enzyme system before they reach your bloodstream in usable form. CBD inhibits several of these enzymes, particularly CYP3A4, CYP2C9, and CYP2C19. These three enzymes are responsible for metabolising a huge share of commonly prescribed drugs, from blood thinners to antidepressants to antiepileptics. CBD also affects UGT enzymes (a separate detoxification pathway used by drugs like lorazepam) and P-glycoprotein, a transporter protein that pumps drugs out of cells and controls how much of a dose actually reaches your brain or bloodstream.

The practical consequence is straightforward, even if the biochemistry isn’t:

When CBD inhibits an enzyme, the drug that enzyme normally breaks down builds up in your system, sometimes to unsafe levels.
When CBD induces an enzyme (which happens with some pathways at certain doses), the drug clears faster and may become less effective.
P-glycoprotein interference can alter how much of a drug crosses into the brain, which matters enormously for sedatives and psychiatric medication.
The effect isn’t universal. It depends on dose, the specific drug, and which enzyme pathway that drug relies on.

This is where the grapefruit comparison earns its place in patient counselling. Grapefruit juice is famous for inhibiting CYP3A4, which is why pharmacists warn against taking it with statins or certain blood pressure medicines. CBD works on an overlapping set of enzymes through a similar mechanism, so the comparison gives people an intuitive shortcut: if your medicine carries a grapefruit warning, treat CBD with the same suspicion.

The analogy has limits, though. Grapefruit affects mainly CYP3A4, while CBD has a broader footprint across CYP2C9, CYP2C19, UGT enzymes, and P-glycoprotein. That means CBD can interact with drugs that have no grapefruit warning at all, including some antiepileptics and immunosuppressants where the clinical stakes are considerably higher than with a missed statin dose.

Pro Tip: If your pharmacist has ever told you to avoid grapefruit with a medicine, mention that when you ask about CBD. It’s a fast way to flag a drug that’s likely to need extra caution.

Which medicines carry the highest risk with CBD

Not every medication interaction matters equally. The drugs that demand real caution are the ones classed as narrow therapeutic index (NTI) medicines, meaning the gap between an effective dose and a harmful one is small. A modest rise in blood level that would be irrelevant for paracetamol can cause serious harm with an NTI drug. One review identified 16 different NTI medications involved in reported adverse interactions with cannabinoids, which is why this category sits at the top of every clinical caution list.

Anticoagulants, especially warfarin. CBD inhibits CYP2C9, the primary enzyme responsible for clearing warfarin. Slower clearance means higher blood concentration and a higher INR, the standard measure of blood-clotting time. An elevated INR raises the risk of spontaneous or excessive bleeding, sometimes without obvious warning signs until a bruise or cut behaves abnormally. Anyone on warfarin who introduces CBD needs closer INR monitoring, not a one-off check.
Immunosuppressants: tacrolimus, sirolimus, and everolimus. These drugs keep transplant patients from rejecting a donor organ, and their dosing window is unforgiving. A small clinical study found that CBD raised tacrolimus Cmax by 4.2-fold and AUC by 3.1-fold when taken together, a jump large enough to push levels into toxic territory. Transplant patients should never introduce CBD without their transplant team’s direct involvement, and therapeutic drug monitoring becomes essential immediately after any change.
Antiepileptics, particularly clobazam. This is the best-documented interaction in the CBD literature, partly because CBD is itself used clinically (as Epidyolex) alongside antiepileptic regimens. Clinical data show CBD increases norclobazam, clobazam’s active metabolite, by roughly 3.4-fold, and clobazam itself by around 1.2-fold. That builds up sedation, and in a condition where seizure control depends on stable drug levels, unmonitored changes are genuinely dangerous.
Antidepressants and antipsychotics. Many of these drugs rely on CYP2D6 and CYP2C19 for clearance, both of which CBD can influence. The concern isn’t usually as dramatic as with warfarin or tacrolimus, but raised drug levels can intensify side effects, and combinations involving serotonergic drugs deserve caution around serotonin syndrome, a rare but serious reaction marked by agitation, rapid heart rate, and high body temperature.
Sedatives, opioids, and other CNS depressants. Here the mechanism is simpler: CBD itself has mild sedative properties in some people, and combining it with benzodiazepines, sleep medication, or opioids can produce additive drowsiness. That additive effect can slow breathing in higher-risk combinations, which is a real safety concern rather than a theoretical one.
Over-the-counter medicines and herbal supplements. It’s easy to assume interaction risk only applies to prescription drugs, but ibuprofen, St John’s Wort, and other supplements metabolised through the same CYP pathways can interact too. If you take anything regularly, prescribed or not, it belongs in the conversation with your pharmacist. Our guide to CBD and ibuprofen covers one of the most common OTC combinations in detail, and readers managing blood pressure should also see our piece on CBD and blood pressure medication.

What the evidence on CBD medicine interactions actually shows

The honest answer is that the evidence is real but uneven. A 2024 systematic review examined reports across 889 individual subjects and 603 cannabis or cannabinoid users, drawing on 31 separate reports where pharmacokinetic changes or adverse events occurred. From that data, researchers flagged 57 common prescription medications carrying a high theoretical probability of interacting with cannabinoids.

That figure sounds alarming, and it should prompt caution, but “theoretical probability” is doing real work in that sentence. Some of those 57 drugs have only case-report evidence behind them, not controlled trials. Others, like clobazam and tacrolimus, have measured pharmacokinetic data with specific fold-increases attached. The strength of evidence varies drug by drug, which is exactly why a blanket “CBD is safe” or “CBD is dangerous” message misses the point.

The numbers that matter most: clobazam’s active metabolite rose roughly 3.4-fold with concurrent CBD, and tacrolimus exposure rose 3.1 to 4.2-fold in a small pharmacokinetic study. Both are large enough to shift a patient from a therapeutic dose into a toxic one.

Three limitations are worth holding in mind whenever you read a headline about CBD interactions:

Most human data comes from small studies or individual case reports, not large randomised trials.
Retail CBD products vary hugely in actual potency, so what a study measured in a pharmaceutical-grade product may not match what’s in a bottle bought online.
Some CBD users report feeling better on other medications, but expectancy and placebo effects contribute to perceived improvement in stress and anxiety symptoms, and feeling fine is not proof that drug levels haven’t shifted underneath the surface.

That last point deserves emphasis. If CBD is genuinely working as a placebo for you in some respects, it can still be interacting with your medication mechanically, in ways you cannot feel until levels become extreme. Subjective wellbeing and pharmacokinetic safety are two entirely separate questions.

Exactly what to do if you take medicines and want to use CBD

None of this means CBD is off the table for someone on regular medication. It means the decision needs structure, not guesswork.

Disclose CBD use to every prescriber and pharmacist, every time. Don’t assume your GP already knows, and don’t leave it out because it’s “just a supplement.” Bring the product name, strength, and ideally a Certificate of Analysis (CoA) so the conversation is based on facts rather than estimates.
Ask about monitoring before you start, not after something feels wrong. For warfarin, that means more frequent INR checks in the weeks after introducing or stopping CBD. For tacrolimus, sirolimus, or antiepileptic medication, it means therapeutic drug monitoring, the routine blood testing that tracks exact drug concentration. This is a baseline-and-follow-up process, not a single check.
Start low and increase slowly. A sudden jump from 10mg to 50mg gives your liver enzymes no time to adjust, and it gives you no way to isolate what caused a change if side effects appear. Slow titration also makes it far easier for your clinician to interpret any lab changes.
Stick with one product once you find it. Switching brands or strengths without telling your prescriber reintroduces the same uncertainty you were trying to eliminate. Consistency matters more than most people expect.
Know the red flags that need urgent attention. Unusual bruising or bleeding, severe or unexpected sedation, sudden confusion, or any signs consistent with transplant rejection or drug toxicity are not “wait and see” symptoms. If you notice any of them after starting CBD, contact a clinician immediately rather than adjusting the dose yourself. Our overview of CBD side effects is a useful reference for distinguishing common, mild effects from genuine warning signs, and if driving is part of your daily routine, our guide to CBD and driving covers impairment considerations worth factoring into that same conversation.
Use your pharmacist, not just your GP. Pharmacists are often faster to consult, have direct access to interaction-checking software, and can flag a problematic combination in minutes. Community pharmacy is genuinely underused for this exact purpose.

Pro Tip: Write down the date you start CBD and any dose change. If a lab result looks unusual weeks later, that timeline is often the fastest way for a clinician to connect cause and effect.

Why product quality changes the interaction risk too

Even a well-informed conversation with your doctor falls apart if the CBD product itself is unreliable. Retail CBD is not regulated with anything close to pharmaceutical consistency, and label inaccuracies are common, including products containing undeclared THC or contaminants the buyer never expected.

That variability matters clinically. If a doctor is trying to judge whether your INR shift is linked to CBD dose, and the product’s actual potency doesn’t match its label, the whole risk calculation becomes guesswork. A bottle labelled 20mg per ml that actually delivers 35mg changes the entire conversation.

Before combining any CBD product with medication, check for:

Lab data from the maker, available when you ask, confirming the actual CBD content matches the label.
Confirmed THC levels, ideally at or below the legal trace limit.
Testing for solvents, heavy metals, and microbial contamination, not just cannabinoid content.
A supplier that publishes this testing openly rather than making you request it.

Pro Tip: Keep a copy of the CoA for whatever product you’re using and bring it to medical appointments. It turns “I take some CBD oil” into a precise, useful clinical detail.

Tools that help you check CBD and drug interactions

You don’t need to rely on memory or guesswork to flag a risky combination. Two resources are worth using before any conversation with a clinician.

Drugs lists 725 drugs with documented interactions with cannabidiol, including 26 classified as major. Enter your medications, and it flags each as major, moderate, or minor, though it can’t account for your specific dose or product quality.
CANN-DIR™ is built for clinical use, mapping cannabinoids against substrate, inhibitor, and inducer lists drawn from FDA prescribing data. It produces a printable report designed specifically to support a doctor’s appointment.
Save or print whichever result you get. Handing a clinician a printed report is faster and more precise than describing the interaction from memory.

A note on how we think about CBD and medication safety

We built Honest CBD Co on the belief that transparency matters more than marketing claims. Our CBD is lab-tested at source, certificates of analysis are gladly shared with anyone who asks, and every label states the exact CBD content in milligrams. If you are on medication, those real numbers are exactly what your pharmacist needs to help you decide safely, and we are always happy to talk through dosing questions: we answer our own emails. Our Full Spectrum CBD Oil comes in clearly labelled strengths (10% and 20%, from £25.99) precisely so that conversation with your doctor is grounded in real numbers, and if you’d rather start with a fixed, predictable dose, our CBD capsules remove the guesswork of measuring drops.

Why the “just tell your doctor” advice usually falls short

Most CBD safety articles end with “consult your doctor,” as though that single sentence resolves the risk. It doesn’t, and treating it as a complete answer is where the conventional advice quietly fails people.

The real problem is that most GPs get minimal training on cannabinoid pharmacology, and a rushed ten-minute appointment isn’t the setting where nuanced enzyme-inhibition risk gets properly assessed. Telling your doctor matters enormously, but it works far better when you arrive with something concrete: a printed interaction report, a Certificate of Analysis, and a clear account of dose and timing. That shifts the conversation from vague reassurance to an actual clinical decision.

I’d also push back gently on the framing that treats CBD as uniquely risky compared with other over-the-counter products. Grapefruit juice, St John’s Wort, and even high-dose vitamin supplements carry comparable enzyme interactions, yet CBD attracts disproportionate alarm partly because it’s newer and less familiar to prescribers. The right response isn’t fear, it’s the same due diligence you’d apply to any substance that touches CYP450 pathways, applied consistently rather than selectively.

Where I do think caution is genuinely underrated is with transplant patients and anyone on antiepileptic medication. The tacrolimus and clobazam data aren’t theoretical scare stories, they’re measured pharmacokinetic shifts with real clinical consequences, and that’s a population where “start low and monitor closely” isn’t optional advice, it’s the only responsible path forward.

Richard

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.